Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Quarterly results
CC transcript
Inv. presentation
|
|
ReShape Weightloss Inc. (RSLS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/17/2021 |
8-K
| Quarterly results |
| 03/10/2021 |
8-K
| Quarterly results |
| 11/12/2020 |
8-K
| Quarterly results |
| 05/14/2020 |
8-K
| Quarterly results |
| 03/26/2020 |
8-K
| Quarterly results |
| 11/14/2019 |
8-K
| Quarterly results |
| 04/01/2019 |
8-K
| Quarterly results |
| 11/14/2018 |
8-K
| Quarterly results |
| 08/14/2018 |
8-K
| Quarterly results |
| 05/14/2018 |
8-K
| Quarterly results |
| 04/02/2018 |
8-K
| Quarterly results |
| 11/14/2017 |
8-K
| Quarterly results |
| 08/08/2017 |
8-K
| Quarterly results |
| 05/16/2017 |
8-K
| Form 8-K - Current report |
| 03/07/2017 |
8-K
| Form 8-K - Current report |
| 11/10/2016 |
8-K
| Form 8-K - Current report |
| 08/04/2016 |
8-K
| Form 8-K - Current report |
| 05/05/2016 |
8-K
| Quarterly results|
Docs:
|
"Form of Amendment No. 1 to the Securities Purchase Agreement dated November 4, 2015, between the Company and the buyers listed therein",
"EnteroMedics Announces Exclusive Federal Government Business Channel Sales Agreement with Academy Medical to Provide vBloc ® Neurometabolic Therapy to U.S. Department of Veterans Affairs Medical Facilities ST. PAUL, Minnesota, May 2, 2016 - EnteroMedics Inc. , the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced an exclusive federal government business channel sales agreement with Academy Medical, LLC to sell its vBloc ® Neurometabolic Therapy to U.S. Department of Veterans Affairs medical facilities. Academy Medical is a certified Service-Disabled Veteran-Owned Small Business specializing in the distribution of medical products to VA and Department of Defense hospitals and community-based...",
"EnteroMedics Announces Closing of $6.25 Million Third Tranche of Previously-Announced Convertible Notes Offering ST. PAUL, Minnesota, May 3, 2016 - EnteroMedics Inc. , the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the third tranche of the $25 million Senior Amortizing Convertible Notes offering announced on November 5, 2015, has closed, for proceeds of $6.25 million. Prior to this most recent closing, EnteroMedics received $12.5 million in proceeds under the agreement. The original securities purchase agreement, which consisted of three tranches, has been amended to allow for a fourth tranche of $6.25 Million. This final tranche must be drawn or waived on or prior to August 15,...",
"EnteroMedics Reports First Quarter 2016 Financial Results ST. PAUL, Minnesota, May 5, 2016 - EnteroMedics Inc. , the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced financial results for the three months ended March 31, 2016. “We had a very productive start to the year with progress made on several fronts, including building momentum in our vBloc ® direct-to-patient marketing strategy and reimbursement efforts, and presentation of data showing the dramatic effect of vBloc ® in the moderately obese,” said Dan Gladney, Chief Executive Officer of EnteroMedics. “We were also pleased to expand the availability of vBloc ® through our recently announced agreement with Academy Medical, and throug..." |
|
| 02/17/2016 |
8-K
| Form 8-K - Current report |
| 11/09/2015 |
8-K
| Quarterly results|
Docs:
|
"EnteroMedics Reports Third Quarter 2015 Financial Results and Commercial Progress Update ST. PAUL, Minnesota, November 9, 2015 - EnteroMedics Inc. , the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced financial results for the three and nine months ended September 30, 2015 as well as an update on its commercial progress to date. With the recent announcement of the appointment of Mr. Dan Gladney as Chief Executive Officer, effective November 16, the Company will host a year-end conference call, in lieu of hosting a third quarter conference call, allowing Mr. Gladney to fully transition into his role. The details of the year-end conference call will be provided at a later date. Commercial U...",
"vBloc ® Therapy Data Demonstrate Two Year Maintenance of Clinically Significant Weight Loss and Sustained Improvements in Obesity Related Risk Factors EnteroMedics Announces Chief Medical Officer, Scott A. Shikora, M.D., F.A.C.S., Awarded 2015 Outstanding Achievement Award from ASMBS" |
|
| 08/06/2015 |
8-K
| Quarterly results |
| 04/30/2015 |
8-K
| Quarterly results|
Docs:
|
"EnteroMedics Reports First Quarter 2015 Financial Results and Provides Business Update ST. PAUL, Minnesota, April 30, 2015 - EnteroMedics Inc. , the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced financial results for the three months ended March 31, 2015 and recent corporate highlights. Recent Corporate Highlights On April 7, 2015, the Company announced that 15 centers were certified and 19 surgeons trained to implant and administer vBloc ® Neurometabolic Therapy. The Company announced today that 15 additional centers have been certified and 21 additional surgeons have been trained, bringing the total number of centers to 30 and surgeons to 40. Once the center is certified, the Company ..." |
|
| 02/18/2015 |
8-K
| Quarterly results |
| 11/12/2014 |
8-K
| Quarterly results |
| 08/07/2014 |
8-K
| Quarterly results |
| 04/30/2014 |
8-K
| Quarterly results |
| 02/12/2014 |
8-K
| Quarterly results|
Docs:
|
"EnteroMedics Reports Fourth Quarter 2013 Financial Results ST. PAUL, Minnesota, February 12, 2014 - EnteroMedics Inc. , the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced financial results for the three and twelve months ended December 31, 2013. For the full year ended December 31, 2013, the Company reported a net loss of $25.8 million, or $0.47 per share. For the three months ended December 31, 2013, the Company reported a net loss of $6.6 million, or $0.11 per share, including research and development expenses of $2.9 million and selling, general and administrative expenses of $3.5 million. Operating expenses were primarily associated with the cost of supporting multiple ongoing clinic...",
"EnteroMedics Announces Food and Drug Administration Advisory Committee Meeting Date for Review of the Maestro ® Rechargeable System for the Treatment of Obesity Center for Devices and Radiologic Health Advisory Committee Scheduled for May 29, 2014 ST. PAUL, Minnesota, February 12, 2014 - EnteroMedics Inc. , the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the U.S. Food and Drug Administration's Office of Device Evaluation has scheduled a meeting of the Center for Devices and Radiologic Health's Advisory Committee on Thursday, May 29, 2014 to review the Maestro ® System delivering VBLOC ® vagal blocking therapy as a treatment for morbid obesity. The CDRH Advisory Committee is an in..." |
|
| 10/31/2013 |
8-K
| Form 8-K - Current report |
| 07/31/2013 |
8-K
| Form 8-K - Current report |
| 05/01/2013 |
8-K
| Quarterly results |
| 02/13/2013 |
8-K
| Quarterly results|
Docs:
|
"EnteroMedics Reports Fourth Quarter 2012 Financial Results ST. PAUL, Minnesota, February 13, 2013 - EnteroMedics Inc. , the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced financial results for the three months and full year ended December 31, 2012. For the full year ended December 31, 2012, the Company reported a net loss of $23.5 million, or $0.59 per share. For the three months ended December 31, 2012, the Company reported a net loss of $7.0 million, or $0.17 per share, including research and development expenses of $3.1 million and selling, general and administrative expenses of $3.6 million. Operating expenses were primarily associated with the cost of supporting the Company's multip..." |
|
| 10/24/2012 |
8-K
| Form 8-K - Current report |
| 08/07/2012 |
8-K
| Form 8-K - Current report |
| 04/24/2012 |
8-K
| Form 8-K - Current report |
|
|
|